Shares of Extendicare Inc. (TSE:EXE – Get Free Report) have been given an average rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is C$23.86.
A number of research firms recently commented on EXE. CIBC increased their target price on shares of Extendicare from C$18.00 to C$22.00 in a research report on Thursday, November 13th. Royal Bank Of Canada raised shares of Extendicare from a “hold” rating to a “moderate buy” rating and lifted their price target for the stock from C$15.00 to C$25.00 in a report on Thursday, December 4th. BMO Capital Markets raised Extendicare from a “hold” rating to an “outperform” rating and upped their price target for the stock from C$21.00 to C$24.00 in a research report on Thursday, December 4th. Natl Bk Canada raised Extendicare to a “strong-buy” rating in a research report on Wednesday, December 3rd. Finally, Canaccord Genuity Group boosted their target price on Extendicare from C$20.00 to C$22.50 in a research note on Thursday, December 4th.
Get Our Latest Stock Analysis on Extendicare
Extendicare Price Performance
Extendicare Dividend Announcement
The firm also recently declared a monthly dividend, which was paid on Monday, November 17th. Shareholders of record on Monday, November 17th were issued a $0.042 dividend. This represents a c) annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, October 31st. Extendicare’s dividend payout ratio (DPR) is currently 46.60%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- Huge robotics rollout underway
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Best $19 you’ll spend this year.
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
